Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MV-CHIK Phase 1 in Healthy Adults
NCT03028441Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2017
- Primary completion
- Jan 2019
- Modality
- Viral Vectors, Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MV-CHIK in chikungunya virus infection (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Chikungunya Virus Serum Antibody Geometric Mean Titer using PRNT50, Mean Fold Change in PRNT50 Anti-CHIKV Antibody Responses and 5 more. Started May 2017; status: completed.
02
Drugs
MV-CHIK
03
Conditions
chikungunya virus infection
Beyond the preview
Go deeper on NCT03028441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03028441.